Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices by Sharma, P. et al.
Early identification of haemodynamic response to
pharmacotherapy is essential for primary prophylaxis of
variceal bleeding in patients with ‘high-risk’ varices
P. SHARMA*, , A . KUMAR*, , B . C. SHARMA* & S. K . SARIN* ,
*Department of Gastroenterology, GB
Pant Hospital, New Delhi, India;
Department of Hepatology, Institute
of Liver & Biliary Sciences (ILBS),
New Delhi, India
Correspondence to:
Dr S. K. Sarin, Room 201, Academic
Block, Department of
Gastroenterology, G B Pant Hospital,
Affiliated to University of Delhi, New
Delhi – 110 002, India.
E-mail: sksarin@nda.vsnl.net.in
Publication data
Submitted 28 February 2009
First decision 10 March 2009
Resubmitted 16 March 2009
Resubmitted 23 March 2009
Accepted 2 April 2009
Epub Accepted Article 8 April 2009
SUMMARY
Background
A beta-blocker is recommended for primary prophylaxis of variceal bleed-
ing; however, only one-third have hepatic venous pressure gradient (HVPG)
response. The role of addition of isosorbide-5-mononitrate (ISMN) to beta-
blocker and benefits of HVPG-guided ‘a la carte’ approach remain unclear.
Aim
To determine the benefits of HVPG-guided pharmacotherapy in primary
prophylaxis of variceal bleeding using beta-blocker and ISMN.
Patients and methods
Consecutive patients of cirrhosis, with high-risk varices, with no previous vari-
ceal bleeding were included. After baseline HVPG, patients received incremen-
tal propranolol to achieve HR of 55 ⁄min. After one-month, HVPGwas repeated
to determine response (<12 mmHg or ‡20% reduction). ISMN was added in
nonresponders andHVPG repeated. Patients were followed up for 24 months.
Results
Of 56 patients (age 47  13, males 79%) from 89 eligible patients, 21 (38%)
responded to beta-blocker alone. Six additional patients responded to com-
bination. Thus, overall 48% (27 ⁄56) patients responded. Variceal bleeding
occurred in seven of 56 (13%) patients [one of 27 (4%) responder, five of 23
(22%) nonresponders and one of six (17%) with unknown response;
P = N.S.]. The actuarial probability of variceal bleeding at median
24 months was 4% in responders and 22% in nonresponders (P < 0.05). Ten
(18%) patients developed adverse effects to propranolol and six of 35 (17%)
tonitrates requiringdose reduction. Risk factors of variceal bleedwere grade
IVvaricesandhaemodynamicnonresponse.
Conclusions
For primary prophylaxis, a beta-blocker is effective in 38% and addition
of ISMN raises the response rate to about half of patients. The HVPG-
guided ‘a la carte’ approach may be considered for these patients.
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INTRODUCTION
The lifetime prevalence of varices in cirrhotics has
been reported to be as high as 80–90%. Variceal
bleeding is a serious complication and it occurs in 30–
40% of the patients with varices. The mortality of
acute variceal haemorrhage has decreased signifi-
cantly, but still ranges between 15 and 20% even with
optimal management.1–3 The incidence of the first var-
iceal bleeding is up to 15% per year in patients with
medium–large varices.4 Because of the high rates of
bleeding and mortality, primary prophylaxis of vari-
ceal bleeding is indicated for patients with ‘high-risk’
varices. Nonselective beta-blocker is the recommended
therapy for primary prophylaxis of variceal bleeding
in these patients.5–7 Beta-blockers reduce the 2-year
incidence of first bleeding in these patients by 40%.8
However, only one-third of patients on beta-block-
ers have a significant reduction in portal pressure in
the form of hepatic venous pressure gradient (HVPG)
response (defined as decrease in HVPG to <12 mmHg
or ‡20% reduction in HVPG from baseline). The role
of addition of isosorbide 5-mononitrate (ISMN) to
beta-blocker for primary prophylaxis is not clear.
Addition of ISMN significantly increases HVPG
response to beta-blockers9 and lowers the rate of first
haemorrhage.10, 11 However, a recent larger trial was
unable to confirm these favourable clinical results and
a greater number of side effects were noted in the
combination therapy group.12
Another question is whether HVPG monitoring
should be performed in patients on pharmacological
therapy. Studies have demonstrated that an HVPG
response is associated with an effective protection
from first variceal bleeding.13–15 However, there are
conflicting results on cost-effectiveness of HVPG
monitoring in primary prophylaxis,16, 17 and the
benefits of HVPG guided ‘a la carte’ approach in
primary prophylaxis of variceal bleeding are uncer-
tain, because the previous trial based on this
approach was small and used a fixed dose of beta-
blocker.18
To answer these questions, we aimed in this study to
determine the clinical and haemodynamic benefits of
HVPG guided pharmacotherapy in primary prophylaxis
of variceal bleeding using beta-blocker and ISMN. The
haemodynamic responders were compared with hae-
modynamic nonresponders for development of first
variceal bleeding.
PATIENTS AND METHODS
Patients
From January 2004 to February 2005, consecutive
patients with cirrhosis, without history of upper gastro-
intestinal (UGI) bleeding were recruited from the
in-patient and out-patient departments of GB Pant
Hospital, New Delhi. Eligible patients who were included
had a diagnosis of cirrhosis based on clinical criteria,
laboratory tests, endoscopic evidence, imaging findings
and liver histology (if available). Patients were aged
18–70 years and had grade III or IV oesophageal varices
as per Conn’s classification19 with the presence of red
colour signs (the ‘high-risk’ varices). None had history
of previous variceal bleeding. The exclusion criteria
were: (i) previous endoscopic treatment – endoscopic
sclerotherapy (EST) or endoscopic variceal ligation
(EVL); (ii) history of use of beta-blockers in previous
3 months; (iii) history of surgery for portal hyperten-
sion; (iv) additional noncirrhotic cause of portal hyper-
tension (extra-hepatic portal vein obstruction or hepatic
venous outflow tract obstruction); (v) Child–Pugh score
‡13; (vi) significant cardiopulmonary or renal disease;
(vii) presence of any neoplasm; (viii) contraindications
to use of beta-blockers (atrio-ventricular block, sinus
bradycardia with heart rate <50 beats ⁄min, arterial
hypotension with systolic blood pressure <90 mmHg,
heart failure, bronchial asthma, peripheral arterial
disease or diabetes needing insulin treatment);
(ix) angle-closure glaucoma, (x) concomitant treatment
for hepatitis B or C; (xi) inability to attend follow-up
and (xii) failure to give consent. The study protocol
conformed to the Helsinki Declaration of 1975 and
was approved by the institutional ethical committee.
Informed consent was obtained from all the partici-
pating subjects. The study was an open-labelled, non-
randomized, single-centre study. Patients were allotted
an enrolment number as per their sequence.
Study design
The study design is shown in Figure 1. Following
inclusion of patients and baseline evaluation,
baseline HVPG was measured. Patients then received
beta-blocker treatment. After 1 month of treatment
with beta-blocker (after achieving the target heart
rate), the HVPG measurement was repeated to deter-
mine the HVPG response. Response was defined as a
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decrease in HVPG to <12 mmHg or a ‡20% reduction
in HVPG from baseline. If the patient was found not
to have responded, ISMN was added. The measurement
of HVPG was then repeated in these patients, for the
third time, after 1 month of ISMN therapy. Patients
who did not respond haemodynamically to propranolol
and ISMN and who did not bleed were continued on
the same drugs. This was done so with a presumption
that such patients may ultimately derive some benefit
from drug therapy even with suboptimal reduction in
portal pressure. Both responders and nonresponders
were followed up for a median of 24 months for
development of first variceal bleeding. The nonrespon-
ders served as a comparative group.
Treatment
The principle of incremental dosing was used to achieve
the target heart rate for propranolol. Propranolol was
started at a dose of 20 mg twice daily and increased on
alternate day to achieve a target heart rate of 55 beats ⁄
min or to the maximal dose of 360 mg ⁄day and contin-
ued if the medication was well tolerated and the systolic
blood pressure remained >90 mmHg.
ISMN was started to the nonresponders to beta-
blockers at 10 mg twice daily and increased to 20 mg
twice daily after 3 days and was continued if it was
well tolerated and the systolic blood pressure remained
>90 mmHg.
On the occurrence of intolerable adverse effects, systo-
lic blood pressure dropping to <90 mmHg or pulse rate
decreasing to <55 ⁄min, the dose of the medication was
decreased stepwise and, if these adverse events persisted,
eventually stopped. Reintroduction of the medication
was attempted if cessation of the medication did not
result in improvement of the reported adverse effects.
Compliance was assessed by interview with the
patients as well as corroboration of the patient’s his-
tory by a member of the family, if present, during
consultation. Blood levels of propranolol and ISMN
were not measured. Noncompliance was defined as at
least one episode of stopping the medication for more
than 3 days. Patients with intolerable side effects
related to ISMN were continued on propranolol alone.
Follow-up
This included clinical assessment once a month for the
first 3 months, then every 3 months till the end of fol-
low-up or in between, if the patient had any com-
plaints. Patients who did not attend the follow-up
visits were called over the telephone or by letter.
Included patients
Baseline HVPG
Beta-blocker to achieve target heart rate of 55/min
Repeat HVPG after 4 weeks
RespondersNonresponders
to beta-blocker
Add ISMN
Response:
HVPG <12 mmHg or
>20% reduction from
baseline
Repeat HVPG after 4 weeks
Responders
Follow-up × 24 monthsFollow-up × 24 months
Nonresponders
to combination
Figure 1. Study design.
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Endpoints
The primary endpoint of the study was the develop-
ment of first variceal bleeding. Secondary endpoints
were haemodynamic response (to therapy with beta-
blocker alone and to therapy with combination of
drugs in beta-blocker nonresponders), UGI bleeding
from any other source, development of adverse effects
and the effect of treatment on systemic and pulmonary
haemodynamics, renal function, ascites and survival.
All patients were instructed to go to the hospital
whenever they experienced melena or hematemesis. In
case of an episode of UGI bleeding, the patient was
admitted to the hospital and evaluated for the cause of
bleeding. An emergency endoscopy was performed.
Variceal bleeding was diagnosed when varices were
actively bleeding or had stigmata of recent bleeding
and ⁄or if fresh blood was observed in the stomach and
varices were the only potential source of bleeding.
Bleeding from portal hypertensive gastropathy (i.e.
nonvariceal bleeding related to portal hypertension)
was diagnosed when such lesions were seen actively
bleeding or had signs of recent bleeding (fibrin clots
or black–brown spots). If the UGI bleeding was arising
from the varices, the patient was treated with EVL plus
somatostatin or terlipressin for 5 days in the ICU.
Blood transfusion was given to keep the haemoglobin
level above 8 gm ⁄dL.
Measurement of HVPG
The haemodynamic studies were performed after an
overnight fast, with full aseptic precautions and under
antibiotic cover. Under local anaesthesia, a 7F central
venous catheter (Arrow; Arrow Medical, Athens, TX,
USA) was placed in the right femoral vein or right
internal jugular vein under fluoroscopic guidance,
using the Seldinger technique.
Hepatic venous pressure gradient was measured by
the standard technique20 in which a 7F balloon tipped
Swan Ganz catheter (Boston Scientific, Natick, MA,
USA) was introduced into the right hepatic vein under
fluoroscopic guidance. The zero reference point was set
at the mid-axillary point. The free hepatic venous pres-
sure (FHVP) was obtained by keeping the catheter free
into the lumen of the hepatic vein. The balloon of the
catheter was then inflated to wedge the lumen of the
hepatic vein. The pressure tracing at this juncture
showed absence of wave forms and the pressure was
labelled as wedged hepatic venous pressure (WHVP).
Presence of wedging was confirmed by injection of
2 mL intravenous contrast which showed absence of
reflux into inferior vena cava and appearance of a sinu-
soidogram. HVPG was obtained by subtracting free from
WHVPs (HVPG = WHVP ) FHVP). All measurements
were performed in triplicate. If the difference between
the two readings of HVPG was more than 1 mmHg, all
the readings were discarded and fresh set of measure-
ments were taken. The normal value of HVPG in our
haemodynamic laboratory is between 1 and 4 mmHg.
Measurement of cardiac output, systemic
vascular resistance and pulmonary vascular
resistance
After measuring HVPG, the balloon catheter was
advanced into the right atrium, pulmonary artery and
then pulmonary capillaries for measurement of the
right atrial pressure (RAP), pulmonary arterial pressure
(PAP) and pulmonary capillary wedge pressure (PCWP)
respectively. Mean arterial pressure (MAP) was mea-
sured simultaneously by introducing the catheter
through femoral artery. Blood samples were obtained
from the pulmonary artery and the femoral artery for
estimating oxygen saturation. Heart rate was derived
from continuous electrocardiogram monitoring. Car-
diac output (CO) was calculated by Fick’s oxygen
method21 as follows: [oxygen consumption (mL ⁄min)] ⁄
[Arterio-venous oxygen difference (mL ⁄L)]. The
systemic vascular resistance (SVR, in dynes · s ⁄ cm5)
was calculated as: (MAP in mmHg ) RAP in
mmHg) · 80 ⁄ [CO (in L ⁄min)]. The pulmonary vascular
resistance (PVR, in dynes · s ⁄ cm5) was calculated as:
(PAP in mmHg ) PCWP in mmHg) · 80 ⁄ [CO (in
L ⁄min)]. CO was indexed by body surface area and
expressed as cardiac index (CI) (L ⁄min ⁄m2).
Statistical analysis
Results were expressed as mean (SD), median (range)
or frequency (%). Comparisons of quantitative variables
were performed by the Student’s t-test or Mann–Whitney
U-test and for qualitative variables by Fisher exact
test. Paired sample t-test or Wilcoxon test was used to
compare paired data. A P-value of <0.05 was consid-
ered significant. Risks of bleeding were calculated with
Kaplan–Meier plots and compared by log-rank test.
For analysing the risk factors for first variceal
bleeding, univariate and multivariate analyses were
performed. Quantitative variables were categorized
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based on their mean or median values. An intent-to-
treat strategy was used in the analysis of the results.
Statistical analyses were performed with the SPSS 15.0
statistical package (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
Eighty-nine cirrhotic patients with high-risk oesopha-
geal varices were enrolled in the study. Fifty-six
patients were included in the study and rest excluded
as per the exclusion criteria (Child–Pugh score ‡13 in
14, hepatic venous outflow tract obstruction in six,
type 1 diabetes mellitus in five, renal failure in four,
hepatocellular carcinoma in two and bronchial asthma
in two patients). The baseline characteristics of the
included patients are shown in Table 1.
Study profile
Study profile in terms of HVPG response is shown in
Figure 2. The median dose of propranolol used was
120 mg (range 60–300 mg). On HVPG measurement
performed at 1-month, 21 ⁄56 (38%) responded to
beta-blocker alone, while 35 ⁄56 (62%) remained non-
responders. These nonresponders were treated with
combination therapy with a median dose of ISMN of
40 mg (range 20–40 mg). Twenty-nine of 35 of these
patients underwent HVPG measurement at 2 months,
while six did not give consent. At 2-month HVPG, six
additional patients became responders, while 29 still
remained nonresponders to combination therapy
(including six who had not given consent for HVPG).
Thus, overall 48% (27 ⁄56) patients responded, either
to beta-blocker alone (n = 21) or to combination
(n = 6). Rest 52% (29 ⁄56), were overall nonresponders.
These nonresponders were, however, continued on the
combination regimen at the same doses, without chan-
ging the treatment options.
Haemodynamic response
Response to beta-blocker alone. The mean baseline
HVPG was 18.0  4.5 mmHg. Haemodynamic response
to beta-blocker alone was achieved in 21 (38%) patients
and rest 35 (62%) were nonresponder to beta-blocker
alone (Table 2). The median HVPG reduction achieved
was 26% in responders. Nonsignificant reduction in
HVPG was noted in the nonresponders to beta-blocker
alone. The mean reduction in the heart rate between
responders and nonresponders did not show any differ-
ence (P = N.S.). Responders to beta-blockers had a sig-
nificant increase in the systemic vascular resistance
index (SVRI: 1459  393 vs. 1683  457 dynesÆs ⁄ cm5,
P = 0.009) and decrease in CI (4.8  1.3 vs. 4.2 
1.2 L ⁄min ⁄m2, P = 0.001), whereas pulmonary vascular
resistance index (PVRI) did not show any change
(80  36 vs. 83  43 dynes.s ⁄ cm5, P = 0.752). Nonre-
sponders to beta-blocker did not have any significant
change in SVRI and PVRI, whereas the CI decreased
Table 1. Baseline characteristics of patients
Parameters Value (n = 56)
Age (years), mean (SD) 47 (13)
Gender, n (%)
Male 44 (79)
Female 12 (21)
Aetiology, n (%)
Hepatitis B 22 (39)
Hepatitis C 12 (22)
Alcohol 13 (23)
Cryptogenic 8 (14)
Autoimmune 1 (2)
Ascites, n (%) 27 (48)
CTP class, n (%)
A 16 (29)
B 27 (48)
C 13 (23)
CTP score (n ⁄ 15), mean (SD) 7.8 (1.9)
Serum bilirubin (mg ⁄ dL), median (range) 1.5 (0.6–6.6)
Serum albumin (g ⁄ dL), mean (SD) 3.3 (0.6)
PT prolongation (s), n (%)
0–3 17 (30)
4–6 17 (30)
>6 22 (40)
Serum creatinine (mg ⁄ dL), mean (SD) 0.7 (0.3)
Oesophageal varices, n (%)
Grade III 45 (80)
Grade IV 11 (20)
Heart rate (beats ⁄min), mean (SD) 89 (9)
MAP (mmHg), mean (SD) 90 (10)
HVPG (mmHg), mean (SD) 18.0 (4.5)
CI (L ⁄min ⁄m2), mean (SD) 5.0 (1.3)
SVRI (dynesÆs ⁄ cm5), mean (SD) 1467 (420)
PVRI (dynesÆs ⁄ cm5), mean (SD) 84 (33)
SD, standard deviation; CTP, Child–Turotte–Pugh; PT,
prothrombin time; MAP, mean arterial pressure; HVPG,
hepatic venous pressure gradient; CI, cardiac index; SVRI,
systemic vascular resistance index; PVRI, pulmonary
vascular resistance index.
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significantly (5.0  1.3 vs. 4.5  1.5 L ⁄min ⁄m2, P = 0.02)
(Table 2).
Response to combination. Nonresponders (n = 35)
were started on ISMN along with their previous dosage
of propranolol. Repeat HVPG on this combination
could be performed in 29 patients while six patients
did not consent for the repeat HVPG measurement.
Six of 29 (21%) patients responded to the combina-
tion treatment. They also had a significant increase in
CI and SVRI, while no difference in PVRI. Nonrespon-
ders had significant reduction in CI, but not in SVRI
and PVRI (Table 3).
Overall response. The overall haemodynamic effect
of therapy in all patients is given in Table 4. There
was a significant reduction in heart rate, HVPG and
CI, while SVRI increased significantly. However, there
was no change in MAP and PVRI.
For analysis, the six patients who did not undergo
third HVPG were included in the nonresponder to
combination treatment group. On comparing patients
with HVPG response (n = 27) with HVPG nonrespon-
ders (n = 29), it was found that no baseline clinical or
laboratory parameter could predict response (Table 5).
Post-therapy heart rate, MAP, CI, SVRI and PVRI were
also not different in these two groups.
Primary endpoint
During a median follow-up of 24 months (range 12–
36 months), first variceal bleeding occurred in seven
of 56 (13%) patients. This bleeding occurred in one of
27 (4%) responders and six of 29 (21%) nonresponders
(log-rank test P = 0.097) (Figure 3). The actuarial prob-
ability of first variceal bleeding at median 24 months
of follow-up was 4% in responders and 24% in nonre-
sponders (P < 0.05). The variceal bleeding in the single
responder occurred at 28 months of follow-up, while
the bleeding in six nonresponders occurred at 13, 14,
17, 19, 24 and 27 months respectively. No variceal
bleeding occurred within the first year of follow-up.
On excluding the six patients who did not undergo
the third HVPG measurement from the analysis, of 50
patients, 27 (54%) were responders and 23 (46%) were
nonresponders. The first variceal bleeding occurred in
six of 50 (12%) patients. This bleeding occurred in one
Nonresponder to
beta-blocker alone
(n = 35)
Nonresponder to
combination
(n = 29)
17.5
13.1
Responder
(n = 6)
2 month1 monthBaseline
20.0
18.0
16.0
14.0
12.0
10.0
18.0 17.9
13.5
Responder
(n = 21)
H
VP
G
 (m
mH
g)
Figure 2. Hepatic venous pressure gradient (HVPG)
response to therapy.
Table 2. Haemodynamic response to treatment with beta-blocker alone (n = 56)
Parameter
Responders (n = 21) Nonresponders to beta-blocker alone (n = 35)
Before After P-value Before After P-value
Heart rate (beats ⁄min) 88 (10) 57 (3) <0.01 89 (9) 57 (3) <0.01
MAP (mmHg) 89 (10) 89 (9) 0.857 91 (10) 89 (10) 0.078
HVPG (mmHg) 18.4 (5.3) 13.4 (4.1) <0.01 17.7 (4.1) 17.9 (3.8) 0.656
CI (L ⁄min ⁄m2) 4.8 (1.3) 4.2 (1.2) 0.001 5.0 (1.3) 4.5 (1.5) 0.028
SVRI (dynesÆs ⁄ cm5) 1459 (393) 1683 (457) 0.009 1483 (452) 1563 (486) 0.217
PVRI (dynesÆs ⁄ cm5) 80 (36) 83 (43) 0.752 86 (32) 87 (34) 0.817
Values are given as mean (SD) except the P-values.
SD, standard deviation; MAP, mean arterial pressure; HVPG, hepatic venous pressure gradient; CI, cardiac index; SVRI, sys-
temic vascular resistance index; PVRI, pulmonary vascular resistance index.
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of 27 (4%) responders and five of 23 (22%) non-
responders (log-rank test P = 0.108). The actuarial
probability of first variceal bleeding at median
24 months of follow-up was 4% in responders and
22% in nonresponders (P < 0.05).
Other secondary endpoints
Five nonresponder patients (17%) developed new
ascites while none of responders developed new ascites
(P = 0.052).
Two patients died during the follow-up, one each in
the responder and nonresponder groups (P = 1.0).
Cause of death in the responder was liver failure, while
in the nonresponder, it was variceal bleeding.
No patient developed renal failure. None of the
patients developed nonvariceal upper GI bleed.
Adverse effects
Ten (18%) patients developed adverse effects to pro-
pranolol (Table 6) requiring dose reduction [seven
(20%) nonresponders and three (14%) responders].
Median duration of development of adverse effects
was 15 days. Six of 35 (17%) patients on ISMN devel-
oped adverse effects to ISMN (Table 6) requiring dose
reduction. Median duration of development of adverse
effects was 4 days.
Risk factors for first variceal bleeding
Univariate analysis for risk factors for first variceal
bleed revealed that grade IV oesophageal varices was
the most important risk factor for variceal bleed
(P = 0.002) followed by haemodynamic nonresponse
to therapy (P = 0.097) (Table 7). Multivariate analysis
also showed the same two factors as independent risk
factors for first variceal bleeding (Table 8).
DISCUSSION
The results of this study demonstrate that for primary
prophylaxis of variceal bleeding, in patients of cirrho-
sis with ‘high-risk’ varices, when beta-blocker is
Table 3. Haemodynamic response to treatment with combination of beta-blocker and ISMN in patients who did not
respond to beta-blocker alone (n = 35)
Parameter
Responders (n = 6)
Nonresponders to combination treatment
(n = 29)
Before After P-value Before After P-value
Heart rate (beats ⁄min) 85 (3) 58 (4) <0.01 90 (10) 58 (3) <0.01
MAP (mmHg) 95 (16) 98 (18) 0.125 90 (8) 88 (6) 0.585
HVPG (mmHg) 18.0 (6.1) 13.1 (4.2) <0.01 16.9 (3.1) 17.5 (3.3) 0.292
CI (L ⁄min ⁄m2) 5.0 (0.9) 4.1 (0.7) 0.024 5.1 (1.4) 4.4 (1.3) 0.044
SVRI (dynesÆs ⁄ cm5) 1418 (351) 1954 (479) 0.005 1454 (435) 1645 (506) 0.226
PVRI (dynesÆs ⁄ cm5) 84 (27) 83 (31) 0.976 92 (35) 94 (28) 0.479
Values are given as mean (SD) except the P-values.
SD, standard deviation; MAP, mean arterial pressure; HVPG, hepatic venous pressure gradient; CI, cardiac index; SVRI,
systemic vascular resistance index; PVRI, pulmonary vascular resistance index.
Table 4. Overall haemodynamic effect of therapy in all
patients
Parameters Baseline
Post-
therapy P-value
Heart rate (beats ⁄min) 89 (9) 58 (3) <0.01
MAP (mmHg) 90 (10) 90 (9) 0.795
HVPG (mmHg) 18.0 (4.5) 15.8 (4.7) <0.01
CI (L ⁄min ⁄m2) 5.0 (1.3) 4.4 (1.4) <0.01
SVRI (dynesÆs ⁄ cm5) 1467 (420) 1662 (491) 0.001
PVRI (dynesÆs ⁄ cm5) 84 (33) 85 (35) 0.793
Values are given as mean (SD) except the P-values.
SD, standard deviation; MAP, mean arterial pressure; HVPG,
hepatic venous pressure gradient; CI, cardiac index; SVRI,
systemic vascular resistance index; PVRI, pulmonary vascu-
lar resistance index.
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administered alone, at a dose to bring down the heart
rate to 55 beats ⁄min, the HVPG response rate is 38%.
When ISMN is added to the beta-blocker nonrespon-
ders, the overall HVPG response rate increases to
about half of all patients. This ‘a la carte’ approach,
with sequential addition of ISMN to nonresponders of
beta-blockers and repeating HVPG for early identifica-
tion of overall nonresponders, helps in categorizing
patients to their bleeding risk profile. The 2-year
actuarial probability of first variceal bleeding in
Table 5. Comparison of over-
all responders and overall
nonresponders Parameters
Overall responders
(n = 27)
Overall
nonresponders
(n = 29) P-value
Baseline
Age (years) mean (SD) 44 (14) 49 (11) 0.155
Gender, n (%)
Male 20 (74) 24 (83) 0.523
Female 7 (26) 5 (17)
Aetiology, n (%)
Hepatitis B 11 (41) 11 (38) 0.080
Hepatitis C 2 (7) 10 (34)
Alcohol 7 (26) 6 (21)
Cryptogenic 6 (22) 2 (7)
Autoimmune 1 (4) 0 (0)
Ascites, n (%) 15 (56) 12 (41) 0.422
CTP class, n (%)
A 8 (30) 8 (28) 0.979
B 13 (48) 14 (48)
C 6 (22) 7 (24)
CTP score (n ⁄ 15),
mean (SD)
7.7 (1.9) 7.9 (2.0) 0.818
Serum bilirubin
(mg ⁄ dL), median (range)
1.6 (0.6–3.7) 1.4 (0.7–6.6) 0.417
Serum albumin (g ⁄ dL),
mean (SD)
3.3 (0.7) 3.2 (0.6) 0.729
PT prolongation (s), n (%)
0–3 8 (30) 9 (31) 0.977
4–6 8 (30) 9 (31)
>6 11 (40) 11 (38)
Serum creatinine (mg ⁄ dL),
mean (SD)
0.7 (0.3) 0.6 (0.2) 0.402
Oesophageal varices, n (%)
Grade III 22 (82) 23 (79) 1.000
Grade IV 5 (18) 6 (21)
Heart rate (beats ⁄min),
mean (SD)
87 (8) 90 (10) 0.216
MAP (mmHg), mean (SD) 91 (11) 90 (8) 0.667
HVPG (mmHg), mean (SD) 18.3 (5.3) 17.6 (3.7) 0.586
Follow-up, mean (SD)
Heart rate (beats ⁄min) 58 (3) 58 (3) 0.731
MAP (mmHg) 91 (12) 88 (6) 0.275
HVPG (mmHg) 13.4 (4.2) 18.2 (4.0) <0.01
CI (L ⁄min ⁄m2) 4.2 (1.1) 4.6 (1.5) 0.285
SVRI (dynesÆs ⁄ cm5) 1744 (467) 1585 (508) 0.231
PVRI (dynesÆs ⁄ cm5) 83 (40) 87 (31) 0.707
SD, standard deviation; CTP, Child–Turotte–Pugh; PT, prothrombin time; MAP, mean
arterial pressure; SVRI, systemic vascular resistance index; PVRI, pulmonary vascular
resistance index; HVPG, hepatic venous pressure gradient.
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responders is 4% and that in nonresponders is 22–
24%. The addition of ISMN causes adverse effects in
17% patients; however, these are usually mild and
subside with dose reduction and the combination can
be continued safely. The only independent risk factors
for first variceal bleeding are grade IV oesophageal
varices and haemodynamic nonresponse to therapy.
As up to two-thirds of patients on beta-blockers do
not have a haemodynamic response, these patients are
exposed to a significant risk of first variceal bleeding.
The role of addition of ISMN to these patients was not
clear. Although it was shown previously by Garcı´a-
Paga´n9 that combination of beta-blocker with ISMN
leads to a higher HVPG response rate, there were con-
troversial results as far as clinical efficacy of
combination treatment in primary prophylaxis is con-
cerned. In a multicentre randomized trial on 146
patients, nadolol plus ISMN was found to be signifi-
cantly more effective than nadolol alone in the long-
term (up to 7 years) use with few side effects,10, 11
Contrary to these results, in another multicentre study
of 349 patients,12 the cumulative probability of first
variceal bleeding in propranolol plus ISMN group was
similar to propranolol plus placebo group. Moreover,
adverse effects were significantly more frequent in the
propranolol plus ISMN group due to a greater inci-
dence of headache. However, this study was different
from ours due to inclusion of patients with varices of
any size, shorter follow-up of 16 months and a higher
drop-out rate. Moreover, all the reported side effects
due to ISMN disappeared promptly after discontinua-
tion of the drug with no deterioration of renal func-
tion or worsening of control of ascites.22 In our study,
we found that addition of ISMN was safe, with minor
adverse effects in one sixth of patients that disap-
peared with dose reduction. Thus our study suggests
that the combination of beta-blocker and ISMN for
primary prophylaxis appears to be more effective and
safe.
Our study suggests that pharmacotherapy for pri-
mary prophylaxis should be HVPG guided. This allows
early identification of beta-blocker nonresponders and
only these patients should be offered ISMN. Subse-
quent HVPG allows early identification of nonrespon-
ders to combination therapy whose bleeding risk is
much higher than the responders. These patients may
be switched over to an alternative therapy. Short of
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Figure 3. Kaplan–Meier graph
showing cumulative probabil-
ity of first variceal bleeding in
responders and nonresponders.
Table 6. Adverse effects observed in patients treated with
propranolol and ISMN
Propranolol
(n = 10)
ISMN
(n = 6)
Tiredness 10 (100) Headache 6 (100)
Dizziness 7 (70) Dizziness 4 (67)
Breathlessness 6 (60) Breathlessness 1 (17)
Poor memory 2 (20) Nausea 1 (17)
Values in parenthesis represent percentages.
ISMN, isosorbide mononitrate.
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HVPG, no parameter can differentiate between respon-
der and nonresponder. Both responders and nonre-
sponders had similar heart rate reduction (almost
55 beats ⁄min). Similarly, no baseline clinical or
laboratory parameter can predict response to pharma-
cotherapy (Table 4).
The ‘a la carte’ approach for pharmacotherapy in
prevention of variceal bleeding was first adopted by
Bureau et al. in 2002.18 In their trial, 34 patients were
treated to prevent a first bleeding episode (n = 20) and
a rebleeding (n = 14). Thirteen patients (38%) were
responders to propranolol. ISMN improved haemody-
namic response in seven cases. Among these 20 (59%)
haemodynamic responders, only two (10%) experi-
enced variceal bleeding compared with nine of 14
(64%) nonresponders (P < 0.05). Using multivariate
analysis, only haemodynamic response was found to
have an independent predictive value for the risk of
variceal bleeding.18 However, there were many criti-
cisms to that study, the first being relatively low
number of patients analysed, thereby leading to a
lack of statistical power, particularly in the subgroup
analysis of patients receiving primary prophylaxis. A
second criticism is that they used a fixed dose of
propranolol in all patients. The individual sensitivity
to beta-blockers differs markedly from patient to
patient, so an incremental dose of propranolol gives
a better response.23 Our study overcame both these
shortcomings. Our patient numbers is almost three
times that of the study by Bureau et al. and we used
the principle of incremental dosing for beta-blocker
therapy. Hence, our results are more robust and the
menu offered is actually ‘a la carte’ rather than
‘menu fixe’.
The nonresponders to combination therapy have a
higher risk of first variceal bleeding (up to 24% in
median 2 years in our study). This bleeding risk is
almost similar to those not on any therapy.4 Thus, it is
essential that we identify them early so that alternative
form of therapy (like EVL) can be offered to them.
Table 7. Univariate analysis of risk factors for first vari-
ceal bleed
Variable*
P-value
(Log-rank test)
Baseline
Age (years)
<47 vs. ‡47 0.561
Gender
Male vs. female 0.428
Aetiology
Hepatitis B vs. rest 0.412
Hepatitis C vs. rest 0.724
Alcohol vs. rest 0.252
Cryptogenic vs. rest 0.792
Ascites
Present vs. absent 0.701
CTP class
A vs. B ⁄C 0.586
Serum bilirubin (mg ⁄ dL)
<1.5 vs. ‡1.5 0.154
Serum albumin (g ⁄ dL)
<3.3 vs. ‡3.3 0.831
PT prolongation (s)
£6 vs. >6 0.439
Serum creatinine (mg ⁄ dL)
<0.7 vs. ‡0.7 0.470
Oesophageal varices
Grade III vs. grade IV 0.002
Heart rate (beats ⁄min)
<89 vs. ‡89 0.713
Mean arterial pressure (mmHg)
<90 vs. ‡90 0.547
HVPG (mmHg)
<17.9 vs. ‡17.9 0.775
Follow-up
Heart rate (beats ⁄min)
<57 vs. ‡57 0.973
Mean arterial pressure (mmHg)
<89 vs. ‡89 0.936
Haemodynamic response in HVPG
Responder vs. nonresponder 0.097
* For quantitative variables mean or median values were
used for categorization.
SD, standard deviation; CTP, Child–Turotte–Pugh; PT, pro-
thrombin time; MAP, mean arterial pressure; HVPG, hepatic
venous pressure gradient.
Table 8. Multivariate analysis of risk factors for first var-
iceal bleed
Variable P-value Odds ratio 95% CI
Serum bilirubin
‡1.5 mg ⁄ dL
0.098 7.7 0.7–85.4
Grade IV oesophageal
varices
0.035 8.6 1.2–63.0
Haemodynamic
nonresponder
0.045 12.4 1.1–145.7
Variables with P-value <0.2 using univariate analysis were
entered into multivariate analysis.
CI, confidence interval.
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Although EVL and beta-blocker therapy is considered
to have same efficacy,24 EVL therapy in pharma-
cotherapy nonresponders would be a logical and a
definitely more effective choice. In our study, the step-
wise haemodynamic approach allowed us to identify
nonresponders by the end of 8 weeks itself.
Although HVPG measurement is a safe procedure,
the acceptability of repeated HVPG measurements in
‘a la carte’ approach needs to be assessed. In our
study, all patients underwent a second HVPG, but six
of 35 (17%) nonresponder patients to beta-blocker did
not give consent for a third HVPG study. Their appre-
hension was partly because of the repeated invasive
nature of the procedure and also because of the
uncertainty regarding the benefit and success of the
combination therapy. Nevertheless, till a reliable non-
invasive portal pressure measuring method becomes
available, we have to rely on HVPG measurements for
guiding therapy in ‘a la carte’ approach.
We found that the independent risk factors for first
variceal bleeding are large variceal size and haemo-
dynamic nonresponse. Even though all our patients
had ‘high-risk’ varices, our finding that grade IV
varices had a higher risk of bleeding than grade III
suggests that it makes more sense to classify them into
four grades as per Conn’s classification19 rather than
just small and large as per recent guidelines.5–7 How-
ever, bleeding risk profile of grade IV varices com-
pared to grade III varices needs to be further studied
in larger trials.
We also studied effects of treatment on systemic
and pulmonary haemodynamics in these patients. We
found that with beta-blocker or combination therapy,
there was a significant reduction in CI and a signifi-
cant increase in SVRI. PVRI remained unchanged with
treatment (Table 4). These changes in systemic haemo-
dynamics were more marked in HVPG responders than
in nonresponders (Tables 2 and 3), thus indicating that
these changes are mediated by both beta-1 and beta-2
blockade. Data are scarce in literature on the effect of
beta-blocker or combination therapy on systemic and
pulmonary haemodynamics. A study by Garcia-Paga´n
et al.25 found that addition of oral ISMN caused a
further and marked fall in portal pressure, without
additional changes in azygos blood flow, but with sig-
nificant additional reductions in hepatic blood flow
()15.5%), CO ()11.5%) and MAP ()22%). Our study
provides further evidence that the hyperdynamic cir-
culatory state of cirrhosis is significantly ameliorated
by this therapy.
In our study, five nonresponder patients (17%)
developed new ascites, whereas none of responders
developed new ascites (P = 0.052). This is an interest-
ing observation and needs further prospective trials
addressing the issue whether haemodynamic response
to portal pressure reducing drugs also helps in preven-
tion of ascites.
Reduction in blood pressure has been an important
concern while using beta-blockers with or without
nitrates and in many series, a significant proportion
of patients are unable to tolerate beta-blockers due to
hypotension. However, in our study, it was interesting
to note that in spite of median 120 mg of propranolol
(all patients) plus 40 mg of ISMN (n = 35), there was
no reduction in MAP (Table 4). In a few previous
studies also, it was noted that beta-blockers with or
without nitrates did not have a significant systemic
hypotensive effect.26–29 The reason for this variation
in effect on MAP in various studies remains
unknown.
There are several limitations in our study. First, in
spite of this being the largest study on primary pro-
phylaxis using the ‘a la carte’ approach, the number of
patients is less than what is needed to show significant
difference in bleeding risk of responders and nonre-
sponders. We found a nonsignificant P-value of 0.097
(log-rank test) on comparing cumulative risk of bleed-
ing in responders and nonresponders. Second, we did
not have a control arm (i.e. a standard propranolol
treatment arm without haemodynamic measurement).
A controlled study would have had much more impact
on clinical decision making. Such a study would have
given us the opportunity to demonstrate, whether the
reduction in the bleeding risk is really worth the effort
of 2 (or even 3) HVPG measurements in asymptomatic
patients. This question cannot be answered conclu-
sively due to the uncontrolled design of the current
study. Third, we did not offer any rescue therapy for
nonresponders. This, however, was intentional, as we
wanted to see whether continuing pressure reducing
drugs in nonresponders is of any benefit at all. It was
disappointing to note that this was not demonstrable
in nonresponders. Fourth, the main aetiology in our
study was predominantly viral. Whether studies on
patients with alcoholic liver disease will show similar
results both with the haemodynamics and compliance
is not known.
It has to be conceded that two or three haemody-
namic assessments are undoubtedly invasive and
represents a major disincentive to use this approach in
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primary prophylaxis. With the invasiveness of this
approach and the cost involved, it could well be
argued that, band ligation may be a preferable
approach. Thus, ‘a la carte’ approach, which identifies
approximately half the patients as being nonrespon-
ders, despite the high intensity work involved, may
represent a limitation of pharmacological approach to
primary prophylaxis.
In conclusion, for primary prophylaxis of variceal
bleeding from ‘high-risk’ varices, beta-blocker is effec-
tive in 38% which increases to 48% on addition of
ISMN to beta-blocker nonresponders. The HVPG
guided ‘a la carte’ approach may help in early identifi-
cation of pharmacotherapy nonresponders who have
24% 2-year actuarial probability of first variceal
bleeding. We also showed that the addition of ISMN to
beta-blockers is safe with minor adverse effects. The
risk factors for first variceal bleeding are grade IV
oesophageal varices and haemodynamic nonresponse
to therapy.
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STUDY HIGHLIGHTS
What is current knowledge?
• Nonselective beta-blocker is the recommended
therapy for primary prophylaxis of variceal bleeding
in patients with ‘high-risk’ varices.
• Only one-third of patients on beta-blockers have
a significant portal pressure reduction.
• The role of addition of isosorbide 5-mononitrate
(ISMN) to beta-blocker is controversial.
• Benefits of hepatic venous pressure gradient
(HVPG) guided ‘a la carte’ approach in primary pro-
phylaxis of variceal bleeding are also unclear.
What is new here?
• Addition of ISMN to beta-blocker nonresponders
raises the response rate to 48% from 38%.
• Early identification of haemodynamic response to
pharmacotherapy is essential for primary prophylaxis of
variceal bleeding in patients with ‘high-risk’ varices.
• As haemodynamic nonresponse to therapy is the
most important risk factor for bleeding, the HVPG
guided ‘a la carte’ approach is recommended for all
patients on primary prophylaxis.
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